Rovina, Nikoletta
Akinosoglou, Karolina
Eugen-Olsen, Jesper
Hayek, Salim
Reiser, Jochen
Giamarellos-Bourboulis, Evangelos J.
Funding for this research was provided by:
Hellenic Sepsis Study Group
Rush Univeristy Medical Center
Article History
Received: 6 April 2020
Accepted: 14 April 2020
First Online: 30 April 2020
Ethics approval and consent to participate
: Written informed consent was provided from all participants. The study was approved by the Ethics Committees of the following hospitals: UnorderedList removed
: Not applicable
: JEO is a co-founder, shareholder, and CSO of ViroGates A/S, Denmark. JEO is an inventor on patents on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark.JR is a co-founder and shareholder of Trisaq, a biopharmaceutical company that develops drugs that target suPAR.EJGB has received honoraria from AbbVie USA, Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc., and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMérieux Inc., InflaRx GmbH, and XBiotech Inc.; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis).All other authors have disclosed that they do not have any conflicts of interest relevant to this submission.